Australia markets closed

Mesoblast Limited (MSB.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.8600-0.0200 (-2.27%)
At close: 04:11PM AEST
Full screen
Previous close0.8800
Open0.8950
Bid0.8600 x 1092600
Ask0.8750 x 5097500
Day's range0.8600 - 0.8950
52-week range0.6100 - 2.0700
Volume509,538
Avg. volume1,366,532
Market cap559.391M
Beta (5Y monthly)2.57
PE ratio (TTM)N/A
EPS (TTM)-0.2040
Earnings date29 Aug 2022 - 02 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.07
  • GlobeNewswire

    Jane Bell Joins Mesoblast Board

    NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking and finance lawyer with 22 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Australia and the United Kingdom, including funds management, mergers, acquisitions, and divestment

  • GlobeNewswire

    Appendix 4C Quarterly Activity Report

    Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended June 30, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 33%, or US$6.8 million, to US$13.9 million compared with US$20.7 million in the comparative q

  • GlobeNewswire

    Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

    NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion titled “Late-Stage Advancements in Heart Failure Therapeutics and Management”, presented by Maxim Group LLC and hosted by